FDA approves new antibiotic for staph, other infections
Editor's Note
The US Food and Drug administration approved Zevtera for treating Staphylococcus aureus bacteremia (SAB) bloodstream infections, which are often acquired in healthcare settings.
In the April 3 announcement, the agency notes the new antibiotic Zevtera (ceftobiprole medocaril sodium for injection) is effective for SAB-infected patients with right-sided infective endocarditis as well as two other conditions: adults with acute bacterial skin and skin structure infections (ABSSSI) as well as community-acquired bacterial pneumonia (CABP) in adult patients and children older than three months.
The full announcement contains further details on efficacy in treating the three conditions, side effects and warnings, and the approval to Basilea Pharmaceutica International Ltd.
Free Daily News
- FDA medical device class 1 recalls trend upward
- Data cast doubt on recommendation to delay weight-loss meds prior to surgery
- AAMI guidance covers sterile processing of dilators, ultrasound probes
- Surgical site infections often caused by preexisting bacteria
- The Joint Commission launches new telehealth accreditation program
- FDA announces class 1 recall for disposable biopsy needle kit
- Report: Consistent, purposeful manager-team engagement reduces RN turnover
- Death, hospital readmission less likely for women treated by female doctors
- FDA announces class 1 recalls for infusion pumps, anesthesia workstation
- Study finds workforce readiness gap in new nurses